Logothetis Georgios, Avramidis Konstantinos, Konstantaki Evanthia, Matziou Vasiliki, Doupis John
Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.
Hippocratio General Hospital, Athens, Greece.
touchREV Endocrinol. 2025 May;21(1):9-13. doi: 10.17925/EE.2025.21.1.7. Epub 2025 Apr 28.
The recent coronavirus disease 2019 (COVID-19) pandemic has induced many challenges in the clinical environment worldwide. In a bid to reduce the exposure of healthcare providers to severe acute respiratory syndrome coronavirus 2 and the utilization of personal protective equipment (PPE), while maintaining optimal patient care, in April 2020, the US Food and Drug Administration issued a new policy, allowing the use of continuous glucose monitoring (CGM) systems in the intensive care unit (ICU) setting. This article aimed to explore the role of real-time continuous glucose monitoring systems in patients in the ICU with COVID-19. The hybrid protocols integrating real-time CGM and point of care seem to be a feasible and safe alternative for the glycaemic management of critically ill patients with COVID-1 9, including the reduction of healthcare providers' exposure and the preservation of PPE, whilst achieving and maintaining optimal glycaemic control.
近期的2019冠状病毒病(COVID-19)大流行给全球临床环境带来了诸多挑战。为减少医护人员接触严重急性呼吸综合征冠状病毒2的机会以及个人防护装备(PPE)的使用,同时维持最佳的患者护理,2020年4月,美国食品药品监督管理局发布了一项新政策,允许在重症监护病房(ICU)环境中使用持续葡萄糖监测(CGM)系统。本文旨在探讨实时持续葡萄糖监测系统在COVID-19重症监护病房患者中的作用。将实时CGM与即时检测相结合的混合方案似乎是对COVID-19危重症患者进行血糖管理的一种可行且安全的替代方案,包括减少医护人员的接触和节省PPE,同时实现并维持最佳血糖控制。